articles
- C. elegans as model for drug discovery. 17:2067-2076. 2017
- Computational screening and design for compounds that disrupt protein-protein interactions. 17:2703-2714. 2017
- Structure Based Design of CYP51 Inhibitors. 17:30-39. 2017
- 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A. 14:2094-2102. 2014
- An overview of naturally occurring histone deacetylase inhibitors. 14:2759-2782. 2014
- Epothilones: From discovery to clinical trials. 14:2312-2321. 2014
- High-throughput screening technologies for botulinum neurotoxins. 14:2062-2080. 2014
- Inhibition of botulinum neurotoxin BoNT/A. 14:2043-2043. 2014
- High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid. 13:837-842. 2013
- Medicinal chemistry design principles for liver targeting through OATP transporters. 13:857-866. 2013
- Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. 11:2997-3021. 2011
- Artificial hematopoietic stem cell niche: bioscaffolds to microfluidics to mathematical simulations. 11:1599-1605. 2011
- Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. 11:696-725. 2011
- Protein-protein interactions and cancer: targeting the central dogma. 11:258-280. 2011
- Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. 10:170-186. 2010
- Hsp90 inhibition with resorcyclic acid lactones (RALs). 9:1419-1435. 2009
- RNA interference-based gene expression strategies aimed at sustained therapeutic inhibition of HIV. 9:1065-1078. 2009
- RNAi and related technologies: applications in medicinal chemistry and drug discovery. 9:1063-1064. 2009
- Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. 9:704-723. 2009
- Orexin receptor antagonists: medicinal chemistry and therapeutic potential. 8:977-987. 2008
- Biosynthesis of enediyne antitumor antibiotics. 8:448-459. 2008
- Recent advances of MEK inhibitors and their clinical progress. 7:1364-1378. 2007
- Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. 6:1883-1896. 2006
- Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. 6:771-785. 2006
- Small molecules and future regenerative medicine. 5:383-396. 2005
- exo-Glycal chemistry: general aspects and synthetic applications for biochemical use. 5:1431-1457. 2005
- Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. 4:1045-1057. 2004
- Micro- and nanotechnologies for studying cellular function. 3:687-703. 2003